In biomarkers we trust?

  title={In biomarkers we trust?},
  author={Monya Baker},
  journal={Nature Biotechnology},
What drug and diagnostic companies want, more than anything, is the ability to predict the future. Rather than waiting years and studying thousands of patients, they want to be able to tell who has a disease, which patients will benefit from what drug and whether a drug will have unintended consequences. Predictive tests are starting to come onto the market. Last December, the US Food and Drug Administration (FDA) approved the first DNA microarray test, the AmpliChip Cytochrome P450 Genotyping… CONTINUE READING
41 Citations
11 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 41 extracted citations


Publications referenced by this paper.
Showing 1-10 of 11 references

A Framework for Biomarker and Surrogate Endpoint Use in Drug Development (US Food and Drug Adminisration

  • J. Woodcock
  • Rockville, MD,
  • 2004

Biomarker development : the road to clinical utility

  • G. De Meyer, F. Shapiro
  • Current Drug Discovery
  • 2003

Post-genomic biomarkers: revolutionizing drug development and diagnostics (D&MD Publications, Westborough

  • K. Rubenstein
  • 2003

report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

  • P. Rolan, Atkinson, A. J., Lesko. L.J. Use of biomarkers from drug discovery through practice
  • Clin. Pharmacol. Ther. 73, 284– 291
  • 2003

the road to clinical utility

  • G. De Meyer, Shapiro, F. Biomarker development
  • Current Drug Discovery 12, 23–27
  • 2003

are we being mislead? Ann

  • T. R. Fleming, DeMets, D. L. Surrogate endpoints in clinical trials
  • Intern. Med. 125, 605–613
  • 1996

Similar Papers

Loading similar papers…